Welcome to our dedicated page for Singular Genomics Systems news (Ticker: OMIC), a resource for investors and traders seeking the latest updates and insights on Singular Genomics Systems stock.
Singular Genomics Systems, Inc. is a pioneering life science technology company headquartered in La Jolla, California. Positioned in the heart of the biotech hub near the Pacific Ocean, Singular Genomics is surrounded by prestigious institutions such as the Salk Institute, Scripps, Sanford Burnham, and UCSD. The company is at the cutting edge of genomics, one of the world's fastest-growing industries, and boasts a dynamic and fast-paced work environment that encourages innovation and results.
Singular Genomics is committed to advancing science and medicine through the development of next-generation sequencing (NGS) and multiomics technologies. Their product portfolio includes the G4 Sequencing Platform and the PX Integrated Solution, each designed to cater to distinct market needs. The G4 Sequencing Platform targets the NGS market, while the PX Integrated Solution focuses on single-cell, spatial analysis, and proteomics markets. These products are applicable in diverse fields such as oncology, immunology, neurology, genetic diseases, infectious diseases, and the human microbiome.
The company also recently introduced the G4X™ Spatial Sequencer, a high-throughput in situ spatial sequencing platform capable of direct RNA sequencing, targeted transcriptomics, proteomics, and fluorescent H&E staining from formalin-fixed, paraffin-embedded (FFPE) tissues. This upgrade to the G4 Sequencing Platform marks Singular Genomics as the only company worldwide to offer capabilities for tissue-based in situ spatial multiomics and NGS on the same instrument.
Singular Genomics prides itself on its strong culture of collaboration and innovation. The company offers competitive benefits, including free gym memberships, a 401k plan, flexible vacation policies, and equity incentives, allowing employees to grow alongside the company. The firm’s mission is to empower researchers and clinicians to advance science and medicine, driving forward the potential of genomics to improve human health.
In recent developments, Singular Genomics' management participated in a panel discussion titled “Emerging Life Science Technologies Across Genomics and Proteomics.” This event highlighted their ongoing commitment to innovation and collaboration within the field. The company continues to make significant strides with the G4X system, which promises unprecedented throughput and capabilities for spatial profiling of tissue, further cementing its role as a leader in genomics technology.
Singular Genomics Systems, Inc. (Nasdaq: OMIC) announced it will report its Q1 2023 financial results after market close on May 9, 2023. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results.
The company specializes in next-generation sequencing and multiomics technologies, with the G4 Sequencing Platform available commercially, enabling fast and accurate genomic sequencing. Additionally, the PX system is under development, focusing on in situ readouts for RNA and proteins in cells and tissues.
For investors interested in the conference call, a live and archived webcast can be accessed through the company’s investor portal.
Singular Genomics Systems, Inc. (Nasdaq: OMIC) reported its fourth quarter and full-year results for 2022, marking a pivotal year with significant milestones. The company achieved its first revenue of $765,000, primarily from three instrument placements. Operating expenses rose to $22.5 million in Q4 2022, driven by increased headcount and infrastructure for the G4 launch. Despite a net loss of $21.1 million in Q4, the loss per share improved to $0.29 from $0.27 year-over-year. For the full year, revenue totaled $765,000, while the net loss decreased to $90.9 million, or $1.28 per share, compared to $2.10 in 2021. Cash reserves stood at $244.6 million.
Singular Genomics Systems (Nasdaq: OMIC) has announced its participation at Cowen’s 43rd Annual Health Care Conference in Boston on March 7, 2023. The company's management will engage in a fireside chat at 8:10 a.m. PT / 11:10 a.m. ET. Interested investors can access a live and recorded webcast of this presentation through their investor relations website.
Singular Genomics is advancing life science technology with its G4 Sequencing Platform and developing the PX system, aiming to enhance research and clinical outcomes through next-generation sequencing and multiomics technologies.
Singular Genomics Systems, Inc. (Nasdaq: OMIC) will report its fourth quarter 2022 financial results on March 2, 2023, after market close. A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. The company specializes in next-generation sequencing and multiomics technologies, with products like the G4 Sequencing Platform designed for rapid and accurate genomic results. Additionally, the PX system is in development to analyze RNA and proteins at the single-cell level. Interested investors can access the call via a live and archived webcast.
Singular Genomics Systems (Nasdaq: OMIC) announced new data validating the performance and versatility of its G4 Sequencing Platform during the AGBT 2023 meeting. This dataset, collected from 11 renowned genomics partners, showcases the platform's high accuracy and adaptability across various applications. Partners include industry leaders like 10x Genomics and QIAGEN. The data suggests that the G4 integrates seamlessly into existing NGS workflows, enhancing speed and flexibility in sequencing tasks. Although the company has ambitious commercialization goals, potential risks remain concerning developing and competing with other products.
Singular Genomics Systems, Inc. (Nasdaq: OMIC) has launched the Max Read™ Kits for single cell applications on its G4 Sequencing Platform at the AGBT 2023 meeting. The kits allow for a market-leading output of 3.2 billion reads per run, priced at $1 per million reads. The G4 platform has increased its flow cell specifications to achieve 80–90% Q30 quality, with throughput now reaching up to 450 million reads for F3 flow cells. The company anticipates shipping to customers in Q2 2023 and aims for the G4 to become the leading benchtop system for single cell applications.
Singular Genomics Systems, Inc. (NASDAQ: OMIC) announced that its G4 Sequencing Platform is now compatible with the 10x Genomics Chromium Single Cell platform through the Compatible Partner Program. This partnership promises enhanced performance for customers, ensuring faster, more accurate, and cost-effective single-cell sequencing results. Jorge Velarde emphasized the G4's flexibility and scalability, while 10x Genomics recognized its accuracy. Additionally, the press release includes forward-looking statements regarding potential revenue and market challenges, highlighting a competitive landscape and the need for strong market acceptance of their products.
FAQ
What is the current stock price of Singular Genomics Systems (OMIC)?
What is the market cap of Singular Genomics Systems (OMIC)?
What does Singular Genomics Systems, Inc. do?
Where is Singular Genomics Systems, Inc. located?
What are some of the key products offered by Singular Genomics?
What is the G4X™ Spatial Sequencer?
What markets do Singular Genomics' products serve?
What are some benefits offered to employees at Singular Genomics?
What recent event did Singular Genomics' management participate in?
How is Singular Genomics contributing to scientific advancements?
What makes the G4X system unique?
Where can investors find more information about Singular Genomics?
